JHU TRAC: Training and Supporting the Next Generation of TB Researchers
JHU TRAC:培训和支持下一代结核病研究人员
基本信息
- 批准号:10431020
- 负责人:
- 金额:$ 99.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-16 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAnimal ModelAreaBaltimoreBasic ScienceBioinformaticsBiological AssayBiometryBiostatistics CoreCessation of lifeClinicalClinical PharmacologyClinical ResearchClinical SciencesClinical TrialsCollaborationsCommunitiesComputer ModelsCost Effectiveness AnalysisCountryDataDevelopmentDiagnosisDiagnosticDisciplineDiseaseEconomic ModelsEducation and OutreachEffectivenessEngineeringEnsureEpidemicEpidemiologyFundingGenerationsGoalsGovernmentHIVHealthHealth Services AccessibilityImageImmunologyIn VitroInterdisciplinary StudyInterventionKnowledgeLaboratoriesMentorsMicrobiologyMissionModelingMycobacterium tuberculosisOutputParticipantPathogenesisPharmaceutical PreparationsPharmacologyPharmacology StudyPoliciesPopulation DynamicsPreventionProductivityProtocols documentationPublic Health NursingResearchResearch PersonnelRoleSamplingScientistServicesSiteSpecific qualifier valueStrategic PlanningSumTalentsTrainingTraining ProgramsTraining SupportTranslational ResearchTuberculosisUnderrepresented PopulationsUnited States National Institutes of HealthUniversitiesWorld Health Organizationanimal imagingbasebiosafety level 3 facilitycareerclinical research sitedesigndiagnostic tooldrug developmentefficacy validationepidemiological modelevidence baseexperienceglobal healthimaging facilitiesimprovedinnovationinterdisciplinary collaborationlarge datasetsmathematical modelmedical schoolsmeetingsmembermicrobialmultidisciplinarynext generationnovelnovel diagnosticspandemic diseasepharmacokinetics and pharmacodynamicspharmacometricspre-clinicalpublic health interventionradiotracerrecruitresearch studysymposiumsynergismtooltraining opportunitytranslational modeltuberculosis treatment
项目摘要
ABSTRACT — JHU TRAC OVERALL
Tuberculosis (TB) remains a major global health problem, and advances in the basic and clinical sciences are
urgently needed to make progress towards the World Health Organization’s End TB Strategy goal of reducing TB
deaths by 95% and new cases by 90% between 2015 and 2035. The Johns Hopkins University (JHU) Center for
Tuberculosis Research (CTR) has been a global leader in TB pathogenesis, translational models, diagnostics, drug
development, pharmacology, public health interventions, and epidemiological and economic modeling for more than
two decades. Research emanating from the CTR and JHU has transformed the treatment of TB infection and
disease, elucidated interactions between TB and HIV drugs, validated the efficacy and effectiveness of new
diagnostic tools, and contributed to the development of evidence-based policies for global TB control, based on the
epidemiology and population dynamics of TB. However, to make further progress in efforts to achieve the END TB
goals, additional innovative, cross-disciplinary and impactful research is critical and a new generation of TB
scientists must be recruited and trained, particularly among groups nationally underrepresented in health-related
research (UHRR). We have assembled a multidisciplinary team of researchers from multiple departments spanning
four JHU schools (Medicine, Public Health, Nursing and Engineering), with complementary expertise in microbial
pathogenesis, immunology, animal models, imaging, clinical trials, diagnostics, epidemiology, pharmacology and
pharmacometrics, computational modeling, and biostatistics, in order to provide added value to the TB research
enterprise at JHU optimize training opportunities for junior investigators and support for new, interdisciplinary
collaborations, with the goal of addressing key knowledge gaps in TB research. The JHU TRAC team comprises
58 researchers, including 32 experienced TB researchers (19 current members of the CTR), 15 senior researchers
new to the TB field, and 11 Early Stage Investigators (ESI). The overarching mission of the JHU TRAC is to advance
TB research by promoting innovative, multidisciplinary collaborations and by recruiting, training and supporting
junior Investigators, especially among UHRR groups, to develop the next generation of leaders in TB research. To
this end, the JHU TRAC will focus on these four areas: 1) Enhance the integration, productivity and impact of JHU
TB research; 2) Provide mentoring, support, and pilot funding for the next generation of TB researchers, and to
increase the pipeline of junior investigators from UHRR groups; 3) Support TB researchers with direct services from
a Clinical Core and three Scientific Cores; 4) Contribute to the END TB goals through global engagement, training,
outreach, and collaboration with partners in high-burden countries. The JHU TRAC is organized into six Cores
(Adminsitrative Core (AC); Developmental Core (DC); Clinical Core (CC); Microbiology, Immunology, Animal
Modeling and Imaging (MIAMI) Core; Pharmacology and Pharmacometrics Core (PPC); and Bioinformatics,
Modeling and Biostatistics Core (BMBC), which will interact closely with each other to promote synergy in TB
research, and ensure that the utility and output of the JHU TRAC is greater than the sum of its parts.
摘要- JHU TRAC概述
结核病(TB)仍然是一个主要的全球健康问题,基础和临床科学的进步正在推动
迫切需要在实现世界卫生组织终止结核病战略减少结核病的目标方面取得进展
在2015年至2035年期间,死亡人数减少95%,新病例减少90%。约翰霍普金斯大学(JHU)
结核病研究(CTR)一直是结核病发病机制,转化模型,诊断,药物治疗和治疗方面的全球领导者。
发展,药理学,公共卫生干预措施,流行病学和经济建模,
二十年CTR和JHU的研究改变了结核病感染的治疗,
疾病,阐明了结核病和艾滋病毒药物之间的相互作用,验证了新的
诊断工具,并为制定全球结核病控制循证政策做出了贡献,
结核病的流行病学和人口动态。然而,为了在努力实现结核病最终目标方面取得进一步进展,
为了实现这些目标,额外的创新性、跨学科和有影响力的研究至关重要,
必须招募和培训科学家,特别是在全国卫生相关领域代表性不足的群体中。
研究(UHRR)。我们已经组建了一个多学科的研究团队,来自多个部门,
四所JHU学校(医学,公共卫生,护理和工程),在微生物领域具有互补的专业知识
发病机理、免疫学、动物模型、成像、临床试验、诊断学、流行病学、药理学和
药物计量学、计算建模和生物统计学,以便为结核病研究提供附加值
企业在JHU优化初级研究人员的培训机会,并支持新的,跨学科的
合作,目标是解决结核病研究中的关键知识差距。JHU TRAC团队包括
58名研究人员,包括32名经验丰富的结核病研究人员(19名现任CTR成员),15名高级研究人员
新的结核病领域,和11个早期阶段的研究人员(ESI)。JHU TRAC的首要使命是推进
通过促进创新的、多学科的合作以及通过招募、培训和支持
初级研究人员,特别是UHRR小组中的初级研究人员,以培养结核病研究的下一代领导人。到
为此,JHU TRAC将重点关注以下四个领域:1)加强JHU的一体化、生产力和影响力
结核病研究; 2)为下一代结核病研究人员提供指导、支持和试点资金,
增加来自UHRR小组的初级研究人员的管道; 3)通过以下直接服务支持结核病研究人员:
一个临床核心和三个科学核心; 4)通过全球参与、培训、
外联以及与高负担国家的伙伴合作。JHU TRAC分为六个核心
(管理核心(AC);发展核心(DC);临床核心(CC);微生物学、免疫学、动物
建模和成像(迈阿密)核心;药理学和药物计量学核心(PPC);和生物信息学,
建模和生物统计学核心(BMBC),它们将相互密切互动,以促进结核病的协同作用
(c)开展研究,并确保JHU TRAC的效用和产出大于其各部分之和。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard E. Chaisson其他文献
Efficacy of Engineering Controls in Reducing Occupational Exposure to Aerosolized Pentamidine
- DOI:
10.1378/chest.102.6.1764 - 发表时间:
1992-12-01 - 期刊:
- 影响因子:
- 作者:
Melissa A. McDiarmid;John Schaefer;Cindy Lynn Richard;Richard E. Chaisson;Byron S. Tepper - 通讯作者:
Byron S. Tepper
The Impact of Prophylaxis on Outcome and Resource Utilization in <em>Pneumocystis carinii</em> Pneumonia
- DOI:
10.1378/chest.107.4.1018 - 发表时间:
1995-04-01 - 期刊:
- 影响因子:
- 作者:
Joel E. Gallant;Sharon M. McAvinue;Richard D. Moore;John G. Bartlett;David L. Stanton;Richard E. Chaisson - 通讯作者:
Richard E. Chaisson
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
药物敏感型肺结核的风险分层治疗
- DOI:
10.1038/s41467-024-53273-7 - 发表时间:
2024-10-30 - 期刊:
- 影响因子:15.700
- 作者:
Vincent K. Chang;Marjorie Z. Imperial;Patrick P. J. Phillips;Gustavo E. Velásquez;Payam Nahid;Andrew Vernon;Ekaterina V. Kurbatova;Susan Swindells;Richard E. Chaisson;Susan E. Dorman;John L. Johnson;Marc Weiner;Amina Jindani;Thomas Harrison;Erin E. Sizemore;William Whitworth;Wendy Carr;Kia E. Bryant;Deron Burton;Kelly E. Dooley;Melissa Engle;Pheona Nsubuga;Andreas H. Diacon;Nguyen Viet Nhung;Rodney Dawson;Radojka M. Savic - 通讯作者:
Radojka M. Savic
Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review
- DOI:
10.1007/s40265-024-02131-3 - 发表时间:
2024-12-28 - 期刊:
- 影响因子:14.400
- 作者:
Violet Chihota;Makaita Gombe;Amita Gupta;Nicole Salazar-Austin;Tess Ryckman;Christopher J. Hoffmann;Sylvia LaCourse;Jyoti S. Mathad;Vidya Mave;Kelly E. Dooley;Richard E. Chaisson;Gavin Churchyard - 通讯作者:
Gavin Churchyard
Richard E. Chaisson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard E. Chaisson', 18)}}的其他基金
JHU TRAC: Training and Supporting the Next Generation of TB Researchers
JHU TRAC:培训和支持下一代结核病研究人员
- 批准号:
10593142 - 财政年份:2022
- 资助金额:
$ 99.66万 - 项目类别:
The Johns Hopkins Center for AIDS Research (JHU CFAR)
约翰霍普金斯大学艾滋病研究中心 (JHU CFAR)
- 批准号:
10268586 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
超短疗程利福喷丁和异烟肼 (1HP) 用于预防未感染 HIV 个体结核病的安全性和耐受性
- 批准号:
10226377 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
超短疗程利福喷丁和异烟肼 (1HP) 用于预防未感染 HIV 个体结核病的安全性和耐受性
- 批准号:
10413161 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
超短疗程利福喷丁和异烟肼 (1HP) 用于预防 HIV 未感染者结核病的安全性和耐受性
- 批准号:
10631078 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
超短疗程利福喷丁和异烟肼 (1HP) 用于预防未感染 HIV 个体结核病的安全性和耐受性
- 批准号:
10018455 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
The Johns Hopkins Center for AIDS Research (JHU CFAR)
约翰霍普金斯大学艾滋病研究中心 (JHU CFAR)
- 批准号:
9322787 - 财政年份:2012
- 资助金额:
$ 99.66万 - 项目类别:
The Johns Hopkins Center for AIDS Research (JHU CFAR)
约翰霍普金斯大学艾滋病研究中心 (JHU CFAR)
- 批准号:
8843334 - 财政年份:2012
- 资助金额:
$ 99.66万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists